1. Diagnosis concealment behaviors and disclosure beliefs are associated with health and quality of life in people with multiple sclerosis.
- Author
-
Leavitt VM, Bae C, Shinohara RT, Weinstein SM, Schmidt H, Aoun SM, Solari A, and Solomon AJ
- Subjects
- Humans, Male, Female, Middle Aged, Adult, Social Stigma, Health Status, Depression diagnosis, Depression psychology, Quality of Life, Multiple Sclerosis psychology, Multiple Sclerosis diagnosis
- Abstract
Background: People with multiple sclerosis (pwMS) struggle with whether, how, and how much to disclose their diagnosis. They often expend resources to conceal their diagnosis, and hold beliefs that it may negatively affect their personal relationships and/or professional opportunities. To better understand these effects, we developed a measure to quantify concealment behaviors and disclosure beliefs. Our main objective is to evaluate relationships of DISCO-MS responses to health and quality of life in a multinational cohort., Methods: Survey responses were obtained for DISCO-MS and PROMIS-MS scales: global health, communication, social roles participation, anxiety, depression, emotional / behavioral dyscontrol, fatigue, lower extremity function, positive affect / well-being, social roles satisfaction, sleep, stigma, upper extremity function, cognitive function, bladder control, bowel control, visual function. Simple linear regression assessed associations., Results: 263 pwMS were include. Higher concealment was associated with higher anxiety (beta= 0.15 [0.07, 0.23]), depression (beta = 0.13 [0.05, 0.21]), emotional dyscontrol (beta = 0.12 [0.04, 0.20]), lower affect / well-being (beta = -0.13 [-0.21, - 0.05]). Higher anticipation of negative consequences of disclosure was associated with lower self-reported physical (beta = -0.15) and mental health (beta = -0.14), lower positive affect / well-being, social roles satisfaction, higher anxiety, depression, emotional dyscontrol, sleep disturbance, and higher perceived stigma., Discussion: These results reveal potential consequences of diagnosis concealment for physical and mental health and quality of life. Raising awareness and implementing interventions may mitigate negative repercussions of concealment., Competing Interests: Declaration of competing interest Disclosures: VML: Speaker honoraria: American Academy of Neurology. Compensation for reviewing: National Institutes of Health, United States Department of Defense. Advisory Board: Biogen. CB: No disclosures to report. RTS: Consulting: Octave Bioscience. Compensation for reviewing: American Medical Association, National Institutes of Health, Department of Defense, Emerson Collective. SMW: No disclosures to report. HS: No disclosures to report. SMA: No disclosures to report. AS: Advisory Board: Almirall, Merck. Non-promotional speaking: Merck, Neurotalk. AJS: Advisory Board: Genentech, Biogen, Alexion, Celgene, Greenwich Biosciences, TG Therapeutics. Consulting: Octave Bioscience. Non-promotional speaking: EMD Serono. Research support: Bristol Myers Squibb. Trainee funding: Biogen. Contracted Research: Sanofi, Biogen, Novartis, Actelion, Genentech/Roche. Expert witness testimony., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF